TWA
TCRT icon

TCI Wealth Advisors’s Alaunos Therapeutics TCRT Stock Holding History

TCI Wealth Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3
Closed -$1K – 1596
2018
Q1 		$1K Buy
3
+1
+50% +$623 ﹤0.01% 1225
2017
Q4 		$1K Buy
2
+1
+100% +$718 ﹤0.01% 1267
2017
Q3 		$1K Buy
+1
New +$888 ﹤0.01% 1205

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's TCRT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 5 shares — an estimated $441 sold.

TCI Wealth Advisors first reported a position in TCRT in Q1 2015 and held it in 33 quarters. The position peaked at $56K in Q2 2015. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 5 Alaunos Therapeutics shares in Q2 2023, an estimated $441.
  • TCI Wealth Advisors first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 33 quarters.
  • TCI Wealth Advisors's Alaunos Therapeutics position peaked at $56K in Q2 2015.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.